Antimycobacterial drugs are used to treat infections caused by members of Mycobacterium genus. Mycobacterium genus includes M. tuberculosis, M. leprae, and M. avium-intracellulare which cause tuberculosis, leprosy, and atypical mycobacteria, respectively. Tuberculosis and leprosy are the most common infections caused by mycobacteria genus. M. avium-intracellulare bacteria are usually present in water and soil and are less harmful to humans compared to M. tuberculosis. Therefore, infections caused by these bacteria are called atypical and non-tuberculous infections. Infections caused by mycobacteria are treatable, but usually require more than one medicine due to the tendency of bacteria to develop resistance to drugs. Increase in government initiatives for the treatment of TB, rise in prevalence of mycobacterial diseases such as tuberculosis and leprosy, surge in awareness about infections, favorable reimbursement policies, and resistance developed by bacteria for antimycobacterial drugs are the major factors expected to drive the global antimycobacterial drugs market. However, low availability of proper diagnostic facilities for diseases such as leprosy is likely to restrain the market. Development of novel drug delivery systems affecting bacterial resistance and reducing the amount of drugs required for the complete treatment of infection are the recent trends in the global antimycobacterial drugs market.
The global antimycobacterial drugs market can be segmented based on product type and distribution channel. In terms of product type, the antimycobacterial drugs market can be classified into drugs used for tuberculosis, drugs used for leprosy, and drugs used for atypical mycobacteria. The drugs used for tuberculosis segment can be bifurcated into first line drugs and alternative drugs. First line drugs include isoniazid, ethambutol, streptomycin, and rifampicin. Alternative drugs include PAS (para amino salicylate) and ethionamide. The drugs used for leprosy segment includes Dapsone (diamino diphenyl sulfone), clofazimine, and rifampicin. Atypical mycobacteria drugs include azithromycin and clarithromycin. The drugs used for tuberculosis segment held the largest share of the antimycobacterial drugs market in 2017 due to campaigns organized by governments to spread awareness about tuberculosis. The segment is expected to sustain its leadership position during the forecast period. Based on distribution channel, the global antimycobacterial drugs market can be divided into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the antimycobacterial drugs market in 2017 due to easy availability of leprosy and tuberculosis medications in government hospitals. The segment is expected to continue to dominate the market from 2018 to 2026.
In terms of region, the global antimycobacterial drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Middle East & Africa dominated the global market in 2017 due to high prevalence of TB and related co-infections in the developing countries. According to WHO, in 2017, 10 million people were infected with TB in the region, and 1.6 million succumbed to the disease (including 0.3 million with HIV). The market in Asia Pacific is anticipated to expand at the highest CAGR owing to rise in prevalence of mycobacterial diseases, surge in awareness, increase in per capita income, and improvement in health care infrastructure.
Major players operating in the global antimycobacterial drugs market include Bayer AG, GlaxoSmithKline plc, Lupin Limited, Pfizer, Inc., Macleods Pharmaceuticals, Novartis AG, Systopic Laboratories Pvt. Ltd., AstraZeneca plc, Sanofi, Zydus Cadila, and Merck & Co., Inc.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.
TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.
Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:
Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.
Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.
Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.